Moderate

Pulmonary alveolar proteinosis

surfactant accumulation · Respiratory
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Pulmonary alveolar proteinosis is accumulation of surfactant-derived material in alveoli, most commonly autoimmune (anti-GM-CSF antibodies). It causes progressive breathlessness and hypoxaemia with a characteristic crazy-paving CT pattern; whole-lung lavage is the mainstay treatment.

Red flags

  • Severe refractory hypoxaemia
  • Superimposed opportunistic infection
  • Rapid deterioration
  • Secondary PAP from undiagnosed haematological malignancy

Assessment

Differential diagnosis

  • Pneumocystis jirovecii pneumonia
  • Pulmonary oedema
  • Lipoid pneumonia
  • Organising pneumonia
  • Diffuse alveolar haemorrhage
  • Hypersensitivity pneumonitis

Investigations

  • HRCT chest (crazy-paving: ground glass with interlobular septal thickening)
  • Serum anti-GM-CSF antibody (diagnostic of autoimmune PAP)
  • BAL showing milky, PAS-positive proteinaceous material
  • Lung function (restriction, low DLCO) and resting/exertional oximetry
  • Exclude secondary causes (haematological disease, dust exposure, infection)

Management

  • Suspect in progressive dyspnoea with crazy-paving on CT disproportionate to symptoms
  • Confirm with serum anti-GM-CSF antibody and characteristic BAL findings
  • Classify as autoimmune, secondary or congenital
  • Assess severity with oxygenation and lung function
  • Observe mild/asymptomatic disease as some stabilise spontaneously
  • Perform whole-lung lavage for significant hypoxaemia or functional impairment
  • Consider inhaled/subcutaneous GM-CSF therapy in autoimmune disease
  • Treat secondary PAP by addressing the underlying condition
  • Monitor for superimposed opportunistic infection (nocardia, mycobacteria, fungi)
  • Follow up with serial imaging, physiology and lavage as needed

Drugs & doses

Inhaled GM-CSF (e.g. sargramostim/molgramostim) for autoimmune PAP
Supplemental oxygen as required
Treat secondary infection with pathogen-directed antimicrobials
Rituximab or plasmapheresis in refractory autoimmune disease (selected centres)

Disposition

Specialist / national PAP centre for whole-lung lavage and GM-CSF therapy; monitor for infection.

Complications & pitfalls

  • Respiratory failure
  • Secondary opportunistic infection (especially Nocardia)
  • Pulmonary fibrosis in chronic disease
  • Recurrence requiring repeated lavage

Exam pearls

  • Crazy-paving with disproportionately mild symptoms should prompt consideration of PAP
  • Anti-GM-CSF antibody confirms the common autoimmune form non-invasively
  • Whole-lung lavage remains the mainstay for symptomatic disease
  • Be alert for opportunistic infection, particularly Nocardia

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.